Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 8/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.36 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652233 | 1.00 | GCK (0.48) | GCKAKR1C3RORCPTGS2PSIP1 | |
| SCHEMBL3390050 | 0.91 | GCK (0.46) | GCKAKR1C3RORCPTGS2AKR1C2 | |
| SCHEMBL2650366 | 0.91 | GCK (0.46) | GCKAKR1C3RORCPTGS2AKR1C2 | |
| SCHEMBL2650569 | 0.87 | GCK (0.61) | GCKAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2652352 | 0.87 | GCK (0.61) | GCKAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2652180 | 0.84 | GCK (0.47) | GCKAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2652182 | 0.84 | GCK (0.47) | GCKAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL4504951 | 0.81 | GCK (0.45) | GCKAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL4504946 | 0.81 | GCK (0.45) | GCKAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2024348 | 0.81 | AKR1C3 (0.40) | AKR1C3PTGS2PSIP1AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168962-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2010-03-31 | — | — | EP | claimed |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | claimed |
| EP-1594867-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2005-11-16 | — | — | EP | claimed |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | OSI PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | claimed |
| WO-2004072031-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | WO | claimed |
| EP-2168962-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-7214681-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | GPR119, IAPP, SLC5A1 | GCK 60/4885AKR1C3 809/4885RORC 1406/4885 |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | IAPP, GPR119, SLC5A1 | GCK 70/4885AKR1C3 921/4885RORC 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.